Tenax Therapeutics, Inc. (NASDAQ:TENX)
| Market Cap | 44.83M-76.0% |
| Revenue (ttm) | 0 |
| Net Income | -65.76M-51.8% |
| EPS | -1.40-23.9% |
| Shares Out | 26.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 783,312 |
| Open | 1.64 |
| Previous Close | 1.63 |
| Day's Range | 1.62 - 1.72 |
| 52-Week Range | 1.31 - 19.40 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 4.40(+160.36%) |
| Earnings Date | Mar 9, 2027 |
4 qualifying trades · 3 insiders · $6.40M bought in the last 90 days
Tenax Therapeutics, Inc. Stock Analysis — InsiderScore
See top-rated InsiderScore stocks ›Tenax Therapeutics, Inc. scored higher than 29% of companies evaluated by InsiderBuying, and ranked 51st out of 99 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Tenax Therapeutics, Inc. bought $132.8K of stock across 4 purchases in the last 90 days, the largest of them $101.8K.
The average purchase added about 60% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
About TENX
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
5 firms rating TENX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 9, 2027Earnings report
Ask Barron about TENX
$TENX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TENX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TENX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TENX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TENX Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TENX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TENX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TENX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.61M |
| IWMiShares Russell 2000 ETF | $1.52M |
| IWNiShares Russell 2000 Value ETF | $547.68K |
| VXFVanguard Extended Market ETF | $528.66K |
| VTWOVanguard Russell 2000 ETF | $400.06K |
| IWCiShares Micro-Cap ETF | $178.48K |
Estimated from each fund’s disclosed top holdings × AUM
TENX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TENX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: ranks #51 of 99 scored Biotech stocks · sector average 59.3
What’s Behind the Score
News check: Q3 results and updates overshadowed by analyst caution regarding LEVEL trial data, creating net negative coverage tone.
Recent Insider Activity
Insider Score Trend Over Time
+5.8 since Aug 28Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.